Results 81 to 90 of about 3,904 (178)

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease [PDF]

BACKGROUND The efficacy and safety of risankizumab as compared with ustekinumab in patients with Crohn's disease are unknown. METHODS In this phase 3b, multicenter, open-label, randomized, controlled trial with blinded assessment of end points, patients ...
Anschutz, Toni, Panaccione, Remo, Panaccione, R, Ferrante, Marc, D'Haens, Geert, Anschutz, T, Caprioli, F, Atreya, Raja, Schreiber, S, Schreiber, Stefan, Neimark, Ezequiel, Lindsay, JO, Shu, L, SEQUENCE Study Group, Berg, S, Rahier, Jean-François, Danese, Silvio, Siegmund, Britta, Ferrante, M, Dubinsky, Marla, Gionchetti, Paolo, Peyrin-Biroulet, Laurent, Pivorunas, V, Chapman, JC, Cao, Qian, Bossuyt, Peter, Caprioli, Flavio, Chapman, J Casey, Huang, Xiu, Atreya, R, Berg, Sofie, Peyrin-Biroulet, L, Siegmund, B, Cao, Q, Kligys, Kristina, Duan, W Rachel, Duan, WR, Pivorunas, Valerie, Kligys, K, Huang, X, Wallace, Kori, SEQUENCE Study, Dubinsky, M, Bossuyt, P, Shu, Lei, Danese, S, Neimark, E, Colombel, J-F, Wallace, K, Lindsay, James O, D'Haens, G, Colombel, Jean-Frederic, Irving, PM, Irving, Peter M   +53 more
core   +2 more sources

Should TNF inhibitors be avoided in psoriasis patients with latent tuberculosis?

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Fabià Torres‐Betato, Lluís Puig
wiley   +1 more source

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. [PDF]

, 2018
peer reviewedBACKGROUND: Risankizumab, an anti-interleukin 23 antibody, was superior to placebo in achieving clinical and endoscopic remission at week 12 in a randomised, phase 2 induction study in patients with moderately to severely active Crohn's ...
Sandborn, William J, Kaser, Arthur, Franchimont, Denis, Neurath, Markus Friedrich, Robinson, Anne Martin, Selinger, Christian, Ferrante, Marc, Seidler, Ursula, D'Haens, Geert, Padula, Steven S.J., Visvanathan, Sudha, Feagan, Brian, Othman, Ahmed A., Robinson, Anne M, D'Haens, Geert R, Panes, Julian, Zhao, Jun, Soaita, Adina, Böcher, Wulf Otto, Böcher, Wulf O, Robinson, Anne M., Bocher, Wulf O., Feagan, Brian G., Wallace, Kori, Neurath, Markus F, Kim, Kyung-Jo, Othman, Ahmed A.A., Hall, David B, Louis, Edouard, D'Haens, Geert R., Padula, Steven J, Feagan, Brian G, Herichova, Ivona, Kim, Kyung Jo, Sandborn, William J., Dewit, Olivier, Padula, Steven J., Othman, Ahmed A, Sandborn, William W.J., Neurath, Markus F., Boecher, Wulf O., Hall, David B., Minocha, Mukul, Hall, David D.B.   +43 more
core   +1 more source

P927 Long-term outcomes of risankizumab in Crohn’s disease: a multicenter GETAID Study [PDF]

Meeting abstract du "19th Congress of ECCO", Stockholm, Suède, 21-24 février, 2024International audienceBackground Risankizumab is approved for moderate to severe Crohn’s disease (CD).
Roblin, X., Vuitton, L., Gilletta de Saint-Joseph, C., Nancey, S., Abitbol, V., Defrance, A., Paupard, T., Le Berre, C., Geyl, S., Nachury, M., Peyrin-Biroulet, L., Vidon, M., Fumery, M., Altwegg, R., Simon, M., Guillo, L., Biron, A., Duveau, N., Meyer, A., Stefanescu, C., Kirchgesner, J., Uzzan, M, Caillo, L., Buisson, A., Hébuterne, X., Laharie, D., Caron, B., Ah Soune, P.   +27 more
core   +1 more source

Complete clearance of high-impact sites with risankizumab in patients with psoriasis: a 2-year real-world retrospective multicenter cohort study

Journal of Dermatological Treatment
Objectives Plaque psoriasis frequently involves high-impact anatomical sites such as the scalp, nails, and palmoplantar regions, which are associated with significant functional impairment and reduced quality of life.
Margarida Contente, Ana Luísa João, Martim Luz, Pedro Mendes-Bastos, Ângela Roda, Luiz Leite, Joana Valério, Ana Ferreirinha, Bárbara Leal, Maria João Paiva Lopes, Rita Pimenta, Paulo Ferreira, Tiago Torres   +12 more
doaj   +1 more source

Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia

Journal of Dermatological Treatment
Background Biological therapies are effective for psoriasis, but patient responses vary, often requiring therapy switching or discontinuation.Objectives To identify physicians’ prescribing patterns of biological therapies at a referral tertiary center in
Ahmad Alamer, Wejdan Alyazidi, Saad Aldosari, Fatimah Mobarki, Sarah Almakki, Abdullah Alahmari, Mukhtar Alomar, Ziyad Almalki, Tuqa Alkaff, Mohammad Fazel   +9 more
doaj   +1 more source

Clinical insights into IL-23 inhibition: risankizumab for Crohn’s disease through a systematic review and meta-analysis of randomized controlled trials

Therapeutic Advances in Gastroenterology
Background and aims: Crohn’s disease is a chronic inflammatory disorder with rising global prevalence, marked by abdominal pain, diarrhea, and fatigue.
Po-Feng Huang, Tien-Yu Huang, Yi-Chiao Cheng, Peng-Jen Chen, Wei-Kuo Chang, Chao-Feng Chang   +5 more
doaj   +1 more source

Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies

RMD Open
Objective To assess the efficacy of long-term treatment with risankizumab across the updated Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains and key related conditions of psoriatic arthritis (PsA).Methods This post
Filip van den Bosch, Laure Gossec, Frank Behrens, Ricardo Blanco, Laura C Coates, Michael Chen, Linyu Shi, Alexis Ogdie, Roberto Ranza, Ralph Lippe, Ahmed M Soliman, Yael Klionsky, Derek Coombs, Jamie R Urbanik, Thomas Iyile   +14 more
doaj   +1 more source

Real-World Effectiveness and Safety of Risankizumab in Psoriasis: A Comprehensive Analysis from the Saudi Arabia Psoriasis Registry (PSORSA)

Dermatology and Therapy
Introduction Psoriasis is a chronic immune-mediated skin condition that has a substantial impact on patients’ quality of life. The Saudi Arabia Psoriasis Registry (PSORSA) was established to address long-term real-world data (RWD) on systemic and ...
Mohammed Ibrahim Fatani, Abdulaziz Madani, Fahad Alzuriqan, Abdullah Albadri, Ahmed Aljedai, Hajer Almudaiheem, Maysa Tariq Eshmawi   +6 more
doaj   +1 more source

Systematic review and bayesian network meta-analysis: comparative efficacy and safety of six commonly used biologic therapies for moderate-to-severe Crohn’s disease

Frontiers in Pharmacology
BackgroundIn contrast to previous network meta-analysis using classical frequentist methods, we evaluated the efficacy and safety of six frequently-used biologics through a Bayesian method.MethodsWeb of Science, Scopus, CENTRAL, ClinicalTrials.gov and ...
Haohang Su, Haohang Su, Shengwei Xiao, Zhiqing Liang, Zhiqing Liang, Tianrong Xun, Jinfang Zhang, Jinfang Zhang, Xixiao Yang, Xixiao Yang   +9 more
doaj   +1 more source